Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Martínez-Cuadron, D. (David) | - |
dc.creator | Serrano, J. (Josefina) | - |
dc.creator | Mariz, J. (José) | - |
dc.creator | Gil, C. (Cristina) | - |
dc.creator | Tormo, M. (Mar) | - |
dc.creator | Martínez-Sánchez, P. (Pilar) | - |
dc.creator | Rodríguez-Arbolí, E. (Eduardo) | - |
dc.creator | García-Boyero, R. (Raimundo) | - |
dc.creator | Rodríguez-Medina, C. (Carlos) | - |
dc.creator | Martínez-Chamorro, C. (Carmen) | - |
dc.creator | Polo, M. (Marta) | - |
dc.creator | Bergua, J. (Juan) | - |
dc.creator | Aguiar, E. (Eliana) | - |
dc.creator | Amigo, M.L. (Mari Luz) | - |
dc.creator | Herrera, P. (Pilar) | - |
dc.creator | Alonso-Domínguez, J.M. (Juan M.) | - |
dc.creator | Bernal, T. (Teresa) | - |
dc.creator | Espadana, A. (Ana) | - |
dc.creator | Sayas, M.J. (María J.) | - |
dc.creator | Algarra, L. (Lorenzo) | - |
dc.creator | Vidriales, M.B. (María Belén) | - |
dc.creator | Vasconcelos, G. (Graça) | - |
dc.creator | Vives, S. (Susana) | - |
dc.creator | Pérez-Encinas, M.M. (Manuel M.) | - |
dc.creator | López, A. (Andrés) | - |
dc.creator | Noriega, V. (Víctor) | - |
dc.creator | García-Fortes, M. (María) | - |
dc.creator | Chillón, M.C. (María del Carmen) | - |
dc.creator | Rodríguez-Gutiérrez, J.I. (Juan I.) | - |
dc.creator | Calasanz-Abinzano, M.J. (Maria Jose) | - |
dc.creator | Labrador, J. (Jorge) | - |
dc.creator | López, J.A. (Juan A.) | - |
dc.creator | Boluda, B. (Blanca) | - |
dc.creator | Rodríguez-Veiga, R. (Rebeca) | - |
dc.creator | Martínez-López, J. (Joaquín) | - |
dc.creator | Barragán, E. (Eva) | - |
dc.creator | Sanz, M.A. (Miguel A.) | - |
dc.creator | Montesinos, P. (Pau) | - |
dc.date.accessioned | 2022-08-04T09:11:58Z | - |
dc.date.available | 2022-08-04T09:11:58Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Martínez-Cuadrón, D.; Serrano, J.; Mariz, J.; et al. "Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia". Cancers. 14 (11), 2022, 2817 | es |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://hdl.handle.net/10171/63863 | - |
dc.description.abstract | Simple Summary Most adult patients with acute myeloid leukemia (AML) relapse after achieving complete remission with chemotherapy; however, there is no standard second-line (salvage) treatment. We retrospectively investigated 404 patients aged >= 18 years with relapsed/refractory (R/R) AML with an FMS-like tyrosine kinase 3 (FLT3) mutation, treated at a PETHEMA (NCT02607059) site between 1998 and 2018. Patients received salvage treatment with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care (n = 80). Complete remission was achieved by 48% of patients who received intensive therapy vs. 19% with non-intensive therapy. Intensive/non-intensive therapy prolonged overall survival significantly compared with supportive therapy. Of evaluable patients, 22% received an allogeneic stem-cell transplant after complete remission. The majority of patients with FLT3-mutated R/R AML received intensive salvage therapy, with the best outcomes being obtained when intensive salvage treatment was combined with stem-cell transplant. This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant. | - |
dc.description.sponsorship | This study was supported by Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Valencia, Spain [CB16/12/00284]. Medical writing assistance for this research was funded by Daiichi Sankyo. | - |
dc.language.iso | en | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Acute myeloid leukemia | - |
dc.subject | FLT3-ITD mutation | - |
dc.subject | Real-world outcomes | - |
dc.subject | Relapsed | - |
dc.subject | Refractory disease | - |
dc.subject | Salvage therapy | - |
dc.title | Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia | - |
dc.type | info:eu-repo/semantics/article | - |
dc.description.note | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license | - |
dc.identifier.doi | 10.3390/cancers14112817 | - |
dadun.citation.number | 11 | - |
dadun.citation.publicationName | Cancers | - |
dadun.citation.startingPage | 2817 | - |
dadun.citation.volume | 14 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.